Search

Press release: Breaking news on lymph node cancer and plasma cell cancer reported at Hematology Congress in Stockholm, June 13-16, 2013

In order to support high-quality science, the European Hematology Association (EHA) collaborates with 16 Scientific Working Groups (SWGs) and concentrates on fostering activities directed towards basic and translational research.

Read more

Meeting program

Thursday, October 12*All times are in EET.

Read more

Highlights from the SWG

Project groupsPan-European Transfusion Research infrAstructure (PETRA) projectThe European Blood Alliance has provided funding for a health science data project entitled: ‘Towards a Pan-European Transfusion Research infrAstructure (PETRA).

Read more

Meeting Program

Sickle Cell Disease: From Research to Clinical Management
Please note: all times are in Central European Summer Time (CEST)

Read more

HARMONY Alliance: Progress in Using Big Data Technology to Achieve Better Outcomes for Patients with Blood Cancers

HARMONY Alliance: Progress in Using Big Data Technology to Achieve Better Outcomes for Patients with Blood Cancers: HARMONY Alliance is an unparalleled medicine offensive to battle blood cancers by using Big Data analyses.

Read more

Major changes needed for patients to benefit from precision medicine

Precision medicine approaches the treatment of a disease via an individual’s genes, environment, and lifestyle.

Read more

Uptake of CAR T cell therapy in Europe

Feb 05 2019 Posted in Advocacy news Tagged CAR T

Gene (editing) therapy continues to break ground in hematology, showing promising results in tackling severe blood cancers. Yet, its uptake in the European Union is slow, with few patients benefiting from it so far.

Read more

Tutorial on thalassemia focused on best treatment

Almost 90 delegates from Shiraz and other cities in Iran learned how to identify the best treatment for each thalassemia patient at the EHA-SHRC Hematology Tutorial on Thalassemia on May 10-11, 2018 in Shiraz, Iran.

Read more

Targeting the B-cell Receptor in Aggressive B-cell Lymphomas

In collaboration with Dr. Lou Staudt, Pharmacyclics and associate investigators, we performed a clinical trial of a very potent inhibitor of Bruton Tyrosine Kinase (BTK) called ibrutinib.

Read more